IL162434A0 - Treatment of glioblastoma with thymosin-alpha 1 - Google Patents

Treatment of glioblastoma with thymosin-alpha 1

Info

Publication number
IL162434A0
IL162434A0 IL16243402A IL16243402A IL162434A0 IL 162434 A0 IL162434 A0 IL 162434A0 IL 16243402 A IL16243402 A IL 16243402A IL 16243402 A IL16243402 A IL 16243402A IL 162434 A0 IL162434 A0 IL 162434A0
Authority
IL
Israel
Prior art keywords
thymosin
glioblastoma
treatment
alpha
alpha1
Prior art date
Application number
IL16243402A
Other languages
English (en)
Original Assignee
Rhode Island Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhode Island Hospital filed Critical Rhode Island Hospital
Publication of IL162434A0 publication Critical patent/IL162434A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Prostheses (AREA)
IL16243402A 2001-12-10 2002-12-10 Treatment of glioblastoma with thymosin-alpha 1 IL162434A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33714901P 2001-12-10 2001-12-10
PCT/US2002/039329 WO2003049697A2 (en) 2001-12-10 2002-12-10 Treatment of glioblastoma with thymosin-alpha 1

Publications (1)

Publication Number Publication Date
IL162434A0 true IL162434A0 (en) 2005-11-20

Family

ID=23319320

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16243402A IL162434A0 (en) 2001-12-10 2002-12-10 Treatment of glioblastoma with thymosin-alpha 1

Country Status (22)

Country Link
US (1) US20060166870A1 (xx)
EP (1) EP1461063B1 (xx)
JP (1) JP2005516910A (xx)
KR (2) KR20040091611A (xx)
CN (1) CN1615147A (xx)
AT (1) ATE356628T1 (xx)
AU (1) AU2002357115B2 (xx)
BR (1) BR0214848A (xx)
CA (1) CA2469595A1 (xx)
DE (1) DE60218896T2 (xx)
DK (1) DK1461063T3 (xx)
EA (1) EA005822B1 (xx)
ES (1) ES2283653T3 (xx)
IL (1) IL162434A0 (xx)
MX (1) MXPA04005585A (xx)
NO (1) NO20042927L (xx)
NZ (1) NZ533942A (xx)
PL (1) PL370829A1 (xx)
PT (1) PT1461063E (xx)
SI (1) SI1461063T1 (xx)
UA (1) UA77999C2 (xx)
WO (1) WO2003049697A2 (xx)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2288118B1 (es) 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
CN108226016A (zh) * 2018-01-12 2018-06-29 浙江普罗亭健康科技有限公司 肿瘤免疫细胞亚群精准分型的质谱流式检测试剂盒
CN112147326B (zh) * 2020-09-04 2022-04-08 北京大学 一种肿瘤免疫细胞亚群分型精准检测试剂盒

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079127A (en) * 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
US4116951A (en) * 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. [Asn2 ]-thymosin α1 and analogs thereof
US4148786A (en) * 1978-06-26 1979-04-10 American Home Products Corporation Analgesic polypeptide
DE2919592A1 (de) * 1979-05-15 1981-01-15 Max Planck Gesellschaft Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
IT1238231B (it) * 1989-12-18 1993-07-12 Consiglio Nazionale Ricerche Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori
FR2793684B1 (fr) * 1999-05-17 2001-08-10 Ethypharm Lab Prod Ethiques Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant
US6462017B1 (en) * 2000-05-01 2002-10-08 Sciclone Pharmaceuticals, Inc. Method of reducing side effects of chemotherapy in cancer patients

Also Published As

Publication number Publication date
EP1461063A4 (en) 2005-08-31
AU2002357115A1 (en) 2003-06-23
WO2003049697A2 (en) 2003-06-19
PT1461063E (pt) 2007-06-18
KR20100029844A (ko) 2010-03-17
US20060166870A1 (en) 2006-07-27
MXPA04005585A (es) 2005-03-23
KR20040091611A (ko) 2004-10-28
UA77999C2 (en) 2007-02-15
EA005822B1 (ru) 2005-06-30
ES2283653T3 (es) 2007-11-01
DK1461063T3 (da) 2007-05-21
AU2002357115B2 (en) 2007-12-13
NO20042927L (no) 2004-09-09
WO2003049697A3 (en) 2004-01-15
DE60218896D1 (de) 2007-04-26
BR0214848A (pt) 2004-11-09
EA200400755A1 (ru) 2004-12-30
CA2469595A1 (en) 2003-06-19
PL370829A1 (en) 2005-05-30
NZ533942A (en) 2007-01-26
EP1461063A2 (en) 2004-09-29
DE60218896T2 (de) 2007-09-20
CN1615147A (zh) 2005-05-11
JP2005516910A (ja) 2005-06-09
SI1461063T1 (sl) 2007-08-31
ATE356628T1 (de) 2007-04-15
EP1461063B1 (en) 2007-03-14

Similar Documents

Publication Publication Date Title
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
DE60112974D1 (en) Carbolinderivate
MXPA02007099A (es) Compuestos de tiazola, imidazola y oxazola y tratamientos de desordenes asociados con la maduracion de la proteina.
DE60216233D1 (en) Carbolinderivate
DE60042401D1 (de) Fab-i inhibitoren
DE60105418D1 (de) Serinprotease-inhibitoren
GB0011358D0 (en) Novel use
MXPA00012685A (es) Oregano para el tratamiento de parasitos internos y protozoarios.
UY27203A1 (es) Bencimidazoles útiles en el tratamiento de la disfunción sexual
BR0210101A (pt) Combinações antineoplásticas
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
BR0109512A (pt) Imidazopiridinas tricìclicas
SI1377574T1 (xx)
CY1107343T1 (el) ΕΝΑ ΠΡΟΪΟΝ ΣΥΝΔΥΑΣΜΟΥ ΠΟΥ ΠEPΙΛΑΜΒΑΝΕΙ ΜΕΛΑΓΑΤΡΑΝΗ ΚΑΙ ΕΝΑΝ ΑΝΑΣΤΟΛΕΑ ΠΑΡΑΓΟΝΤΑ VIIa
IL162434A0 (en) Treatment of glioblastoma with thymosin-alpha 1
SE0302361D0 (sv) Inhibering av upptagning av monoamin
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
TR200200169T2 (tr) IL-18 inhibitörlerinin kullanımı.
IL139144A0 (en) Mycobacterial inhibitors
PT1042288E (pt) Inibidores de tripeptidil peptidase
ZA200209835B (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or anti-metabolites.
MXPA03001644A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
TR200003084T2 (tr) Paroxetine askorbat
NO20062138L (no) Anvendelse av ifenprodil i behandling av smerte